Rehashing Endocannabinoid Antagonists: Can We Selectively Target the Periphery to Safely Treat Obesity and Type 2 Diabetes?

Journal of Clinical Investigation - United States
doi 10.1172/jci44099
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Society for Clinical Investigation

Related search

The Endocannabinoid System in Obesity and Type 2 Diabetes

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2008English

Can We Safely Target the WNT Pathway?

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2014English

What Can We Plant Now, Safely /

1933English

Obesity and Type 2 Diabetes Mellitus

Internal Medicine: Open Access
2014English

Obesity and Type 2 Diabetes Mellitus

Integrative Obesity and Diabetes
2018English

Can We Use Nanotechnology to Treat Cancer?

Frontiers for Young Minds
2016English

Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?

Current obesity reports
Medicine
2012English

Exocrine Pancreatic Insufficiency in Type 1 and Type 2 Diabetes Mellitus: Do We Need to Treat It? A Systematic Review

Pancreatology
EndocrinologyHepatologyMetabolismGastroenterologyDiabetes
2018English

What Can We Learn From the Vitamin D and Type 2 Diabetes (D2d) Study?

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy